EA201070150A1 - Сконструированные гибридные антитела против альфа v интегрина - Google Patents
Сконструированные гибридные антитела против альфа v интегринаInfo
- Publication number
- EA201070150A1 EA201070150A1 EA201070150A EA201070150A EA201070150A1 EA 201070150 A1 EA201070150 A1 EA 201070150A1 EA 201070150 A EA201070150 A EA 201070150A EA 201070150 A EA201070150 A EA 201070150A EA 201070150 A1 EA201070150 A1 EA 201070150A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- integrina
- heavy chain
- chain variable
- antibodies against
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 abstract 3
- 108010044426 integrins Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к сконструированным антителам, которые специфично связываются с интегриновыми рецепторами, в частности субъединицей альфа V интегринового рецептора. Эти антитела содержат участки связывания антигена (CDR) известного мышиного антитела к интегрину, гибридные вариабельные последовательности легкой цепи, мутированные вариабельные последовательности тяжелой цепи (FR) и модифицированные константные последовательности тяжелой цепи. Эти новые антитела обладают улучшенными иммуногенными и экспрессионными свойствами и вызывают отличные активности, как антиангиогенную, так и противоопухолевую, у людей при монотерапии, но также и прежде всего в комбинации с другими агентами, ингибирующими ангиогенез и опухоль.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07013964 | 2007-07-17 | ||
| PCT/EP2008/005852 WO2009010290A2 (en) | 2007-07-17 | 2008-07-17 | Engineered anti-alpha v- integrin hybrid antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201070150A1 true EA201070150A1 (ru) | 2010-08-30 |
| EA019485B1 EA019485B1 (ru) | 2014-04-30 |
Family
ID=40029330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201070150A EA019485B1 (ru) | 2007-07-17 | 2008-07-17 | Сконструированные гибридные антитела против альфа v интегрина |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8562986B2 (ru) |
| EP (2) | EP2526967A1 (ru) |
| JP (1) | JP5341889B2 (ru) |
| KR (1) | KR101559596B1 (ru) |
| CN (1) | CN101687039B (ru) |
| AU (1) | AU2008277907B2 (ru) |
| BR (1) | BRPI0815567B8 (ru) |
| CA (1) | CA2693863C (ru) |
| CY (1) | CY1113493T1 (ru) |
| DK (1) | DK2167128T3 (ru) |
| EA (1) | EA019485B1 (ru) |
| ES (1) | ES2395799T3 (ru) |
| HK (1) | HK1143523A1 (ru) |
| HR (1) | HRP20120949T1 (ru) |
| IL (1) | IL203269A (ru) |
| PL (1) | PL2167128T3 (ru) |
| PT (1) | PT2167128E (ru) |
| SI (1) | SI2167128T1 (ru) |
| WO (1) | WO2009010290A2 (ru) |
| ZA (1) | ZA201001124B (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009331955B2 (en) | 2008-12-23 | 2015-09-24 | Merck Patent Gmbh | Biomarkers for inhibitors with anti-angiogenic activity |
| WO2011020529A2 (en) * | 2009-08-19 | 2011-02-24 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
| JP6320042B2 (ja) * | 2011-02-11 | 2018-05-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 前立腺癌治療のための抗アルファ−ｖインテグリン抗体 |
| JP6668241B2 (ja) * | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子 |
| RU2017113001A (ru) | 2014-09-17 | 2018-10-17 | Мерк Патент Гмбх | Способ лечения метастазов в кости, предназначенные для этого медикаменты, и способ прогнозирования клинического исхода лечения метастазов в кости |
| KR20170052690A (ko) | 2014-09-17 | 2017-05-12 | 메르크 파텐트 게엠베하 | 고형암 및/또는 이의 전이 치료 방법, 그에 따른 약제, 및 고형암 및/또는 이의 전이 치료의 임상 결과 예측 방법 |
| PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
| NZ731633A (en) | 2014-11-21 | 2022-01-28 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| JP7034914B2 (ja) * | 2015-11-23 | 2022-03-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体 |
| WO2017088974A2 (en) * | 2015-11-23 | 2017-06-01 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| EP3510407A1 (en) | 2016-09-08 | 2019-07-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating nephrotic syndrome |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045931A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| EP3577137A1 (en) | 2017-02-02 | 2019-12-11 | Merck Patent GmbH | Preferred pairing of antibody domains |
| CN108948206B (zh) * | 2017-05-23 | 2022-08-23 | 赵磊 | 一种抗egfr/pd-1双靶向抗体、其制备方法及用途 |
| AU2018346264A1 (en) | 2017-10-03 | 2020-04-23 | Merck Patent Gmbh | Cysteine engineered antigen-binding molecules |
| WO2019089544A1 (en) * | 2017-11-01 | 2019-05-09 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
| EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| CN113015747A (zh) | 2018-10-19 | 2021-06-22 | 默克专利股份公司 | 用于治疗结肠直肠癌的阿比妥单抗 |
| KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
| CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN114366749B (zh) * | 2020-10-15 | 2023-06-30 | 中国人民解放军海军军医大学 | 整合素抑制剂在制备治疗肾癌的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK281142B6 (sk) | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
| DK0719859T3 (da) | 1994-12-20 | 2003-10-20 | Merck Patent Gmbh | Anti-alfa V-integrin monoklonalt antistof |
| JP3461945B2 (ja) | 1994-12-26 | 2003-10-27 | 株式会社日本製鋼所 | 高低圧一体型タービンロータの製造方法 |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| HUP0303199A2 (hu) | 2001-02-19 | 2003-12-29 | Merck Patent Gmbh | Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására |
| JP4741242B2 (ja) * | 2002-11-26 | 2011-08-03 | アボット バイオセラピューティクス コーポレイション | 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体 |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| KR20060002667A (ko) | 2004-07-03 | 2006-01-09 | 삼성전자주식회사 | 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브 |
| CN101351477B (zh) * | 2005-12-30 | 2011-11-16 | 默克专利有限公司 | 具有降低的免疫原性的抗cd19抗体 |
| WO2007084620A2 (en) | 2006-01-19 | 2007-07-26 | Bassler G Scott | Rapid food chiller |
-
2008
- 2008-07-17 EP EP12004296A patent/EP2526967A1/en not_active Withdrawn
- 2008-07-17 AU AU2008277907A patent/AU2008277907B2/en active Active
- 2008-07-17 KR KR1020107003397A patent/KR101559596B1/ko active IP Right Grant
- 2008-07-17 EP EP08784834A patent/EP2167128B1/en active Active
- 2008-07-17 EA EA201070150A patent/EA019485B1/ru not_active IP Right Cessation
- 2008-07-17 US US12/669,408 patent/US8562986B2/en active Active
- 2008-07-17 PT PT87848347T patent/PT2167128E/pt unknown
- 2008-07-17 ES ES08784834T patent/ES2395799T3/es active Active
- 2008-07-17 CN CN200880024003.1A patent/CN101687039B/zh active Active
- 2008-07-17 JP JP2010516422A patent/JP5341889B2/ja active Active
- 2008-07-17 PL PL08784834T patent/PL2167128T3/pl unknown
- 2008-07-17 DK DK08784834.7T patent/DK2167128T3/da active
- 2008-07-17 WO PCT/EP2008/005852 patent/WO2009010290A2/en active Application Filing
- 2008-07-17 SI SI200830845T patent/SI2167128T1/sl unknown
- 2008-07-17 CA CA2693863A patent/CA2693863C/en active Active
- 2008-07-17 BR BRPI0815567A patent/BRPI0815567B8/pt active IP Right Grant
-
2010
- 2010-01-12 IL IL203269A patent/IL203269A/en active IP Right Grant
- 2010-02-16 ZA ZA2010/01124A patent/ZA201001124B/en unknown
- 2010-09-28 HK HK10109278.2A patent/HK1143523A1/xx unknown
-
2012
- 2012-11-21 HR HRP20120949AT patent/HRP20120949T1/hr unknown
- 2012-12-21 CY CY20121101248T patent/CY1113493T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2693863C (en) | 2017-10-03 |
| BRPI0815567B1 (pt) | 2019-06-04 |
| KR101559596B1 (ko) | 2015-10-12 |
| CN101687039A (zh) | 2010-03-31 |
| ES2395799T3 (es) | 2013-02-15 |
| WO2009010290A3 (en) | 2009-04-09 |
| SI2167128T1 (sl) | 2013-01-31 |
| AU2008277907B2 (en) | 2013-08-22 |
| JP5341889B2 (ja) | 2013-11-13 |
| EP2526967A1 (en) | 2012-11-28 |
| IL203269A (en) | 2014-11-30 |
| EA019485B1 (ru) | 2014-04-30 |
| PL2167128T3 (pl) | 2013-03-29 |
| EP2167128B1 (en) | 2012-10-24 |
| JP2010533480A (ja) | 2010-10-28 |
| DK2167128T3 (da) | 2012-12-03 |
| CA2693863A1 (en) | 2009-01-22 |
| AU2008277907A1 (en) | 2009-01-22 |
| PT2167128E (pt) | 2013-01-24 |
| ZA201001124B (en) | 2010-11-24 |
| BRPI0815567B8 (pt) | 2021-05-25 |
| CY1113493T1 (el) | 2016-06-22 |
| HRP20120949T1 (en) | 2012-12-31 |
| US20100254977A1 (en) | 2010-10-07 |
| CN101687039B (zh) | 2014-04-16 |
| EP2167128A2 (en) | 2010-03-31 |
| US8562986B2 (en) | 2013-10-22 |
| BRPI0815567A2 (pt) | 2015-02-18 |
| HK1143523A1 (en) | 2011-01-07 |
| KR20100057010A (ko) | 2010-05-28 |
| WO2009010290A2 (en) | 2009-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201070150A1 (ru) | Сконструированные гибридные антитела против альфа v интегрина | |
| NZ592215A (en) | c-MET ANTIBODIES | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| AR099812A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr | |
| NZ724971A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
| GEP20135930B (en) | ANTI-cMET ANTIBODY | |
| NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ712765A (en) | Antibodies that bind csf1r | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
| NZ592214A (en) | Improved Interleukin-6 receptor antibody molecule | |
| TR201815254T4 (tr) | Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari | |
| UA106070C2 (ru) | Антитело, которое специфически связывается с egfr и her3 | |
| PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
| CR20110577A (es) | Proteínas de unión a il-1 | |
| WO2013173496A3 (en) | Cd33 antibodies and use of same to treat cancer | |
| PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| CO6410312A2 (es) | Moléculas de anticuerpo que tienen especificidad por humano ox40 | |
| WO2006116592A3 (en) | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells | |
| NZ600262A (en) | Anti-her3 antibodies and uses thereof | |
| NZ597447A (en) | Humanised antibodies to toll-like receptor 2 and uses thereof | |
| RS53760B1 (en) | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES | |
| PH12014501783B1 (en) | Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody | |
| PE20131209A1 (es) | Anticuerpos anti-fap |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |